DOSAGE INDEX / SINGLE
IGF-1 LR3
Research, reported schedules and supply planning.
Examine IGF-1 LR3 heart-cell and animal findings, distinguish organ growth from muscle gain, and assess limits of potency and exposure claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 20–50 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8 weeks; source also mentions 12 weeks
- Route / research model
- Subcutaneous
The source notes glucose-related concerns. LR3 is not interchangeable with other IGF-1 preparations.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
An acidic-diluent option is awaiting product and concentration confirmation. No GA-water or acetic-acid formulation has been assigned.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 1 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 2003 study used LR3 IGF-1 in fetal sheep and cultured fetal cardiomyocytes. It found increased heart growth without an increase in individual cardiomyocyte size. In culture, a DNA-synthesis marker increased, and blocking either ERK or PI3K signaling abolished that response. The investigators interpreted the findings as supporting cell division rather than hypertrophy in this developmental setting. [2]
- In a seven-day guinea-pig experiment, LR3 increased the relative weights of several organs, including the adrenals, gut, kidneys and spleen. Overall body-weight gain and carcass composition were not significantly improved. The investigators also observed changes in circulating IGF measurements. [3]
- Investigators studying experimentally suppressed lactation in rats tested several IGF analogues, including Long-R3-IGF-I. These analogues did not restart lactation in that model, whereas prolactin and growth hormone did. Reduced interaction with binding proteins did not make the tested IGF preparations substitute for those hormones on this endpoint. [1]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original analogue comparison
- Original paper and methods
- Conlon and colleagues, original abstract
- Biomolecules (MDPI)Further reading · Listed in reference bibliography.
- Dopinglinkki (FINCIS Anti-Doping Authority)Further reading · Listed in reference bibliography.
- Mayo Clinic / IBM MicromedexGeneral guidance · Listed in reference bibliography.
- Centers for Disease Control and Prevention (CDC)General guidance · Listed in reference bibliography.
- Drugs.comFurther reading · Listed in reference bibliography.
- Immunize.org (Immunization Action Coalition)General guidance · Listed in reference bibliography.
- Mayo ClinicGeneral guidance · Listed in reference bibliography.
- Frontiers in Bioengineering & BiotechnologyFurther reading · Listed in reference bibliography.
- Drug Testing and Analysis (PubMed)Further reading · Listed in reference bibliography.
- Centers for Disease Control and Prevention (CDC)No destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.